Efficacy and safety of pyrotinib combined with albumin-bound paclitaxel as first-line treatment for HER2-positive metastatic breast cancer in patients previously treated with adjuvant and/or neoadjuvant trastuzumab therapy: The stage 1 results of a single-arm, phase 2 prospective clinical trial.
Xiaochu ManJie HuangShujuan SunDongdong ZhouBaoxuan ZhangShu FangFangchao ZhengChao LiXinzhao WangWei HuangLinlin WangQingqing HeHui FuYan ZhangChangrui LiuLin DongXianguang ZhaoLiang XuXiao SunBingjie FanLihua SongZhengbo ZhouJinming YuHuihui LiPublished in: Clinical and translational medicine (2024)
This study demonstrates that pyrotinib plus albumin-bound paclitaxel as a first-line treatment regimen shows good efficacy and manageable safety for patients who have received adjuvant and/or neoadjuvant trastuzumab for HER2-positive metastatic breast cancer. Besides, a significant association was identified between the expression levels of TLR3 and RET and the PFS in patients.
Keyphrases
- metastatic breast cancer
- end stage renal disease
- newly diagnosed
- clinical trial
- ejection fraction
- chronic kidney disease
- prognostic factors
- randomized controlled trial
- early stage
- squamous cell carcinoma
- immune response
- inflammatory response
- epidermal growth factor receptor
- poor prognosis
- locally advanced
- study protocol
- phase ii
- binding protein
- replacement therapy